BD Respiratory Viral Panel

Innovation that simplifies. Clinical differentiation that counts.

The BD Respiratory Viral Panel for BD MAX™ System simultaneously detects and differentiates SARS-CoV-2, influenza A, influenza B, and/or respiratory syncytial virus.[1]

Answering the need for accurate and efficient clinical differentiation

RSV
24.8 million episodes per year[2]

Flu
1 billion cases per year[3]

COVID-19
similar symptoms to other viral respiratory Infections[4]

SARS-CoV-2, influenza (flu), and respiratory syncytial virus (RSV) are 3 major viral respiratory infections with overlapping signs and symptoms making them difficult to differentiate without diagnostic testing.[4,5]

RSV in particular is increasingly recognized as an important public health concern.[5] **Globally, RSV may be responsible for 3.2 million hospitalizations and 118 200 deaths in children younger than 5 years.[6]** It also exacerbates pre-existing respiratory conditions in adults and may cause serious respiratory illness in the elderly.[5,7] **In one study, 41% to 70% of hospitalizations in adults with influenza-like illness were due to RSV.[8]**

Testing is the only way to confirm the diagnosis and identify potential co-infection, which may help manage the spread of infections, allow continue surveillance, implement adequate patient management strategies, **especially critical for children, elderly, and coinfected patients.[4,5,9,10]**

In a seasonal or pandemic infection climate, your lab may face unprecedented volumes of testing that can impact workflow efficiency. **You need accurate, rapid diagnostic solutions that provide clinically meaningful results to inform patient management strategies.[4,8]**

BD Respiratory Viral Panel for BD MAX™ System

- **4 results,** from **1 specimen,** in 1 single run[1]
- **Clinically meaningful results** that inform patient management strategies[5,8]
- **Increased testing** capacity[11]
- **High sensitivity** and specificity[1]

Streamlined integration into existing workflow with the BD MAX™ System

The **BD MAX™ System offers you a fully integrated, automated real-time PCR platform** with a broad menu of molecular IVD and open-system tests.[12]

- Less than 1.5 minutes hands-on time per sample[13]
- 24 patient results in just over 2 hours[14]
- 96 samples per 8 hour shift[14]

Snap

Assemble unitized reagent strips with extraction and PCR reagents.

Load

Load the Sample Buffer Tubes, racks and PCR cartridges.



Go

Come back in just over 2 to 3 hours for results.*

Catalogue number	Assay Name	Targets	Box configuration
445215**	BD Respiratory Viral Panel for BD MAX™ System	SARS-CoV-2 (N1, N2 in the same channel); Flu A, Flu B, RSV	24 tests per box
44500301†	BD SARS-CoV-2 reagents for BD MAX™ System	SARS-CoV-2 N1, SARS-CoV-2 N2	24 tests per box

**This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under EUA for use by authorized laboratories; BD MAX™ Respiratory Viral Panel has been authorized only for the detection of nucleic acid of SARS-CoV-2, flu a, flu b, and RSV, not for any other viruses or pathogens; and the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb- 3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

†This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under EUA for use by authorized laboratories; BD SARS-CoV-2 Reagents for BD MAX™ System has been authorized only for the detection of nucleic acid of SARS-CoV-2, not for any other viruses or pathogens; and the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb- 3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

For more information, please visit: go.bd.com/BDMAX-RVP

*Assay times may vary.
Flu, influenza; IVD, in vitro diagnostics; IVD, in vitro diagnostics; PCR, polymerase chain reaction; RSV, respiratory syncytial virus.

References: 1. BD Respiratory Viral Panel for BD MAX™ System Package Insert (P0261). **2.** GBD 2016 Lower Respiratory Infections Collaborators. *Lancet Infect Dis.* 2018;18(11):1191–210. **3.** WHO. *8 Things to know about pandemic influenza.* Updated March 2019. Accessed July 2022. https://www.who.int/news-room/feature-stories/detail/8-things-to-know-about-pandemic-influenza. **4.** CDC. *Similarities and Differences between Flu and COVID-19.* Updated January 2022. Accessed 27 May 2022. www.cdc.gov/flu/symptoms/flu-vs-covid19.htm. **5.** NFID. *Respiratory Syncytial Virus (RSV).* Updated February 2022. Accessed 27 May 2022. https://www.nfid.org/infectious-diseases/rsv/. **6.** Shi T et al. *Lancet.* 2017;390(10098):946–58. **7.** McKimm-Breschkin JL et al. *Antiviral Res.* 2022;197:105227. **8.** Ali A et al. *Int J Infect Dis.* 2020;90:170–80. **9.** Musuuza JS et al. *PLoS One.* 2021;16(5):e0251170. **10.** Swets MC et al. *Lancet.* 2022;399(10334):1463–4. **11.** Wei JS. *Aust J Gen Pract.* 2020;49(10):683–6. **12.** BD MAX™ System User's Manual. Becton, Dickinson and Company: Sparks, MD. **13.** Felder RA et al. *J Lab Autom.* 2014;19(5):468–73. **14.** Hirvonen JJ et al. *Eur J Clin Microbiol Infect Dis.* 2015;34(5):1005–9.

bd.com
BD Life Sciences, 7 Loveton Circle, Sparks, MD 21152-0999, USA Tel: 1.800.638.8663